Wolff, Daniel http://orcid.org/0000-0001-7015-3190
Fatobene, Giancarlo
Rocha, Vanderson
Kröger, Nicolaus http://orcid.org/0000-0001-5103-9966
Flowers, Mary E.
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation (n/a, n/a, n/a)
Article History
Received: 13 January 2021
Revised: 14 June 2021
Accepted: 22 June 2021
First Online: 3 July 2021
Competing interests
: D.W. has received honoraria from MACO, Mallinckrodt, Neovii Pharmaceuticals, Novartis AG, and Takeda Pharmaceutical Company Limited. G.F. has an advisory role and has served on speakers’ bureaus for Janssen Global Services LLC. N.K. has received research support from Celgene, Novartis AG and RIEMSER Pharma GmbH; speaker honoraria from Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc., Janssen Global Services LLC, Kite, Neovii Pharmaceuticals, Novartis AG, and Sanofi. MEF has received research support from Incyte and Pharmacyclics LLC including AbbVie Inc.; speaker honoraria from Astellas Pharma US, Inc., Janssen Global Services LLC, and Mallinckrodt; and served as a consultant for CSL Behring, Fresenius Kabi AG, and Pharmacyclics LLC. V.R. has no conflict of interest to report.